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Abstract Breast cancer is a collection of diseases with
distinct molecular traits, prognosis, and therapeutic options.
Luminal A breast cancer is the most heterogeneous, both
molecularly and clinically. Using genomic data from over
1,000 Luminal A tumors from multiple studies, we analyzed
the copy number and mutational landscape of this tumor
subtype. This integrated analysis revealed four major sub-
types defined by distinct copy-number and mutation profiles.
We identified an atypical Luminal A subtype characterized
by high genomic instability, TP53 mutations, and increased
Aurora kinase signaling; these genomic alterations lead to a
worse clinical prognosis. Aberrations of chromosomes 1, 8,
and 16, together with PIK3CA, GATA3, AKT1, and MAP3K1
mutations drive the other subtypes. Finally, an unbiased
pathway analysis revealed multiple rare, but mutually
exclusive, alterations linked to loss of activity of co-repres-
sor complexes N-Cor and SMRT. These rare alterations were
the most prevalent in Luminal A tumors and may predict
resistance to endocrine therapy. Our work provides for a
further molecular stratification of Luminal A breast tumors,
with potential direct clinical implications.
Keywords Luminal A breast cancer  Breast cancer
genomics
Introduction
Evidence from multiple studies converges in defining
breast cancer as a collection of distinct diseases with dif-
ferent molecular traits, prognosis, and therapeutic options.
These diseases are mostly characterized by the status of
hormone and growth factor receptors. Estrogen receptor
(ER), progesterone receptor (PR), and the Her2 tyrosine
kinase play a major role in determining the molecular
phenotype of the tumor and dictate treatment [1–5]. In the
clinic, the most frequently occurring type of breast cancer
is Her2-, ER?, and/or PR?, which represents *150,000
cases each year in the US.
RNA expression-based signatures [6, 7] provided further
insights into the diversity of breast tumors. By expression
profiling, the large majority of ER? and/or PR? tumors are
of the ‘‘luminal subtypes’’ [7, 8]. These tumors can be sub-
divided into Luminal A and Luminal B, with the former being
typically low grade and associated with a better prognosis
[9]. Luminal A is overall the most frequently occurring
breast cancer expression subtype in the population. mRNA-
derived subtypes also include Basal-like breast tumors,
which are predominantly negative for ER, PR, and Her2, and
Her2-enriched tumors, which are positive for Her2 (Fig. 1a).
Recently, major genomic studies further investigated the
heterogeneity of breast tumors using multiple genomic tech-
nology platforms and approaches [10–16]. The most compre-
hensive of these studies, from The Cancer Genome Atlas
(TCGA), assayed over 800 breast tumors with six different
platforms including SNP arrays for DNA copy number
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alterations (CNA), whole exome sequencing, mRNA expres-
sion microarrays, DNA methylation, and protein expression
and phosphorylation using reverse phase protein arrays (RPPA)
[10]. Collectively, these studies revealed further complexity
and diversity between and within the known subtypes.
In particular, a rather heterogeneous spectrum of CNAs
and somatic mutations has been observed across luminal
tumors [10–12]. Luminal A and Luminal B tumors have
been associated with multiple and distinct copy number-
driven clusters in both the dataset from TCGA [10] and the
one from METABRIC [12], indicating that different copy
number changes characterize subsets of these tumors
(Fig. 1b). Similarly, despite an overall low mutation rate
per tumor, Luminal B and especially Luminal A tumors
have the highest number of genes mutated more frequently
than expected by chance as a class [10]. We confirmed this
trend by integrating three different datasets (TCGA [10],
Broad [16], and WashU [11]) and estimated the statistical
significance of recurrence in the unified dataset (Fig. 1c;
Table 1). Importantly, Luminal heterogeneity extends to
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Fig. 1 a Schematic stratification of breast cancer subtypes based on
receptor status, ER and Her2, and PAM50 mRNA-derived signatures.
b The table shows statistically significant intersections between the
PAM50 subtypes (arranged horizontally) and copy number-driven
clusters (arranged vertically) from the METABRIC and TCGA
datasets. c Average number of mutations per sample (white) and
number of recurrently mutated genes (black) are shown for the four
major PAM50 subtypes. Luminal tumors have fewer mutations per
samples, but they tend to affect similar genes. d Boxplot statistics of
disease survival is shown for deceased patients from the METABRIC
dataset across the four major PAM50 subtypes. While Luminal A
tumors have the longest average survival, they also have the largest
diversity
Table 1 Luminal A breast cancer cohorts
Cohort No. of
samples
Data analyzed in this
study
Reference





METABRIC 721 CNA Curtis et al. [12]
Survival
Broad 45 Somatic mutations Banerji et al. [16]
Sanger 79a Somatic mutations Nik-Zainal et al.
[14, 15]
Wash U 25 Somatic mutations Ellis et al. [11]







410 Breast Cancer Res Treat (2013) 141:409–420
123
the highest median overall survival, are also characterized
by the most variability in survival (Fig. 1d). Moreover, it
has been shown that the risk of late mortality in this sub-
type persists at least over 10 years after initial diagnosis,
and is higher than in the other subtypes in the long term
[17].
These preliminary observations point to Luminal A
breast cancer as the most heterogeneous both molecularly
and clinically. The diversity and incidence of this tumor
call for in depth genomic studies to explain its molecular
heterogeneity and link it to clinical outcome.
To this purpose, we integrated data from six different
datasets to explore the genomic complexity of over 1,000
Luminal A tumors (Table 1). We used the TCGA dataset
consisting of 209 Luminal A tumors as a discovery dataset
(Table S1) and confirmed our findings in the other cohorts.
We identified reproducible subgroups within this subtype,
each of which showed distinct DNA CNA, somatic muta-
tions, pathway alterations, and clinical outcome.
Materials and methods
Genomic data
Data from the TCGA study is accessible through the
TCGA web portal at https://tcga-data.nci.nih.gov/tcga/
tcgaHome2.jsp. Data from METABRIC dataset was made
available upon request and is now accessible through the
European Genome–phenome Archive (EGA) with the
accession number EGAS00000000083. Raw and pre-pro-
cessed aCGH data for the Russnes et al. combined dataset
can be accessed through the Gene Expression Omnibus
(GEO) repository with accession numbers: GSE8757 [18],
GSE20394 [19], and GSE19425 [20]. Mutation data for the
Ellis et al. and Banerji et al. dataset are available as sup-
plemental information within the respective publications.
The datasets used in this manuscript can be explored using
the cBio Cancer Genomics Portal at http://www.cbioportal.
org/public-portal/ [21].
Recurrent mutations in breast cancer subtypes
In this work, we account for somatic mutations reported by
multiple studies [10, 11, 16]. To estimate statistical sig-
nificance of recurrent mutations across multiple datasets,
we integrated the full set of reported mutations from these
studies and used the binomial distribution to model the
somatic mutation frequencies of genes. Given N samples,
to estimate if a gene had a higher somatic mutation rate
(mutations per nucleotide) than expected by chance, we
evaluated if a gene with K observed non-silent mutations
(summed over all tumor samples: K ¼PNi¼1 ki) and a
global coding sequence of length L (summed over all tumor
samples: L = l * N) had more mutations than expected,
i.e., the average somatic mutation rate for all genes (G)















From the set of p-values we estimated corresponding
false discovery rates, or q-values, using the Benjamini–
Hochberg procedure [22].
Copy number clustering
DNA copy number data were produced and processed for
TCGA at the Broad Institute [10]. Briefly, copy number
levels were inferred from Affymetrix SNP 6.0 CEL files by
Birdseed and tangent normalization. Segmentation was
then performed by Circular Binary Segmentation [23].
Copy number clustering was performed on normalized and
segmented copy number data. A unified breakpoint profile
(region by sample matrix) was derived by combining all
breakpoints across all samples and determining the mini-
mal common regions of change. Unified breakpoint profiles
were computed using the R package CNTools [24] from
Bioconductor [25] (http://bioc.ism.ac.jp/2.5/bioc/html/
CNTools.html). Hierarchical clustering was done using
the R function hclust, with manhattan distance and Ward’s
agglomeration method [26].
Cluster centroids for each copy number cluster derived
from the Luminal A TCGA dataset were computed by
averaging cluster member features (unified breakpoints).
For each centroid we determined the most intrinsically
variable breakpoints using the median absolute deviation
(MAD) measure. Unified breakpoints with MAD [ 0.1
were selected to define the cluster centroids. Average MAD
values for this subset is threefold higher than the average of
the remaining breakpoints, and twofold higher than the
overall average (Fig. S1).
Samples from the METABRIC dataset have been
assigned to the cluster whose centroid shows the highest
correlation. Pearson correlation coefficient is a scale-
independent measure and, thus, able to overcome the dif-
ficulty of comparing copy number values obtained with
different platforms and on different scales. Nonetheless, we
identified few samples (20 out of 594) with low correlation
values with each centroids (pearson \ 0.1). This subset is
characterized by flat copy number spectra, such that all
probes have identical values close to zero, with the
exception of a few isolated probes likely to be either arti-
facts of the array or germline copy number variation
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(CNV). These flat samples have been assigned to the Copy
Number Quiet subtype.
The quality of the clusters obtained with the centroids
has been evaluated by different metrics: the clusters show
similar proportions as those observed for the TCGA dataset
(Fig. 1b), in-group proportion (IGP) values determined as
in [27] are statistically significant (p \ 0.001 for all clus-
ters, Fig. 1b), and copy number pattern of alterations are
remarkably similar to those observed in the TCGA dataset
(Fig. S2).
Survival analysis
Survival analysis on the METABRIC dataset has been per-
formed using the R package survival (http://cran.r-project.
org/web/packages/survival/index.html) [26]. Patient follow-
up has been limited to 15 years, and deaths related to other
causes have been ignored in the analysis. The same analysis
was performed for the Russnes et al. [19] dataset consisting
of 77 Luminal A samples and combined three different
cohorts: Ull cohort [19] (26 Luminal A samples), MicMa
cohort [20] (9), and Chin cohort [18] (42).
Cox regression multivariate analysis was performed
suing the coxph function from the survival R package.
Multivariate analysis was used to assess dependencies
between the classification induced by the Copy Number
High (CNH) cluster and multiple covariates: tumor size,
grade, stage, and age at diagnosis. This information was
available for 468 Luminal A samples in the METABRIC
dataset.
Subtype enrichment analysis
Given the tremendous heterogeneity displayed by Luminal
A breast tumors, we analyzed the overall spectrum of
genomic alterations across different subtypes looking for
copy number subtype-specific patterns. Our approach relies
on the general abstraction of gene alteration per sample,
where each alteration belongs to one of the three catego-
ries: (a) gene is altered by mutations; (b) gene is primarily
altered by CNA, and mRNA expression levels correlate
with copy number changes; (c) ‘‘Wild-card’’ events (e.g.,
gene shows aberrant mRNA expression and/or methylation
status independent of mutations and copy number).
These categories rely on two systematic approaches: for
mutations we selectively analyzed the list of SMGs iden-
tified by the algorithm MuSiC [28], for copy number we
analyzed frequently amplified and deleted region of interest
(ROI) as identified by GISTIC [29]. We used the set of
wide copy number gains and losses as the wild-card events.
First, we selected the chromosome arms that were found to
be recurrently gained or lost by GISTIC in [10]. Second,
for each event we classified a sample as altered if segments
accounting for at least 50 % of the whole chromosome arm
length had values above (gain) or below (loss) selected
thresholds. In this study, we used T = 0.15 as the absolute
value for the threshold, where gains are defined by copy
number level [T and losses by copy number levels \-T.
To systematically look for subtype-specific genomic
events, we developed a method called Subtype-Enriched
Alterations (SEA). Subtype enrichment is tested in two
steps: (1) the distribution of alterations is compared to the
expected distribution given in the number of samples that
belong to each subtype by a goodness-of-fit test; (2) a
hypergeometric p-value is derived for the subtype with the
highest percentage of alterations when compared against
all others. Enrichment p-values are then corrected for
multiple testing [22]. Alterations in each category are tes-
ted separately and treated independently.
Differential mRNA expression analysis
To characterize the CNH subtype, beyond CNA and
somatic mutations, we looked for genes differentially
expressed between CNH tumors and the rest of Luminal A.
We tested each gene by ANOVA, computed nominal p-
values and corrected for multiple testing. High level
amplification of the 8q region in the CNH group strongly
influences this analysis with a high presence of genes
located in this region. For this reason we used slightly less
strict thresholds to select genes with nominal p-
value \ 0.05 and FDR-corrected q-value \ 0.2.
Using this procedure we extracted two lists, one for
genes that are up-regulated in CNH tumors, and one for
genes that are down-regulated in the same set when com-
pared to the other Luminal A tumors. Each list has been
tested for functional enrichment using the DAVID Func-
tional Annotation Tool [30].
Interestingly, despite a high number of genes from the
highly amplified genomic region 8q21–24, only 3 out of 59
genes associated to ‘‘mitotic cell cycle’’ (GO: 0000278) are
in this locus. Thus, mRNA up-regulation driven by this
amplification does not seem to be related with mitosis
regulation, spindle assembly, and chromatids segregation.
We repeated the same functional enrichment test [30] after
removing genes from 8q21–24, and separately for the up-
regulated genes in this region to untangle potential differ-
ent phenotypes associated to this copy number amplifica-
tion and to other mRNA aberrations independent of it.
Up-regulated genes in CNH Luminal A that are not in
the 8q21–24 region are similarly highly enriched for
‘‘mitosis cell cycle’’ (GO: 0000278), but also for related
processes like ‘‘cell division’’ (GO: 0051301), ‘‘spindle’’
(GO: 000581), and ‘‘nuclear division’’ (GO: 0000280).
These categories show elevated expression of both Aurora
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kinase A and B, as well as several genes in their pathways
(e.g., PLK1, CDC25B, CCNA2, CDK1, INCENP, BIRC5,
CDCA3/5/8, KIF2C). On the other hand, up-regulated
genes in 8q21–24 were not found to be enriched for any
functional annotation.
Mutual exclusivity analysis
All pairwise tests of mutual exclusivity were done using
the switching permutation procedure described in [31].
This permutation strategy has the desirable property of
preserving both number of alterations per gene and number
of alterations per samples.
Mutual exclusivity modules (MEMo) were identified
using the algorithm MEMo [31]. MEMo automatically
identifies mutually exclusive alterations targeting fre-
quently altered genes that are likely to belong to the same
pathway. Genomic events were defined, as described in the
previous section, following the ‘‘gene alteration per sam-
ple’’ abstraction and including focal copy number altered
regions from GISTIC and recurrently mutated genes
identified by MuSiC. Wild-card events included NF1
down-regulation (\1.5 standard deviations from the aver-
age) observed in 12 cases. The corresponding oncoprints
for these modules are shown in Fig. S3 highlighting sample
specific alterations in each module (samples are in the
columns, altered genes in the rows). Module oncoprints
were generated using the cBio Cancer Genomics Portal
[21].
Results
The landscape of Luminal A CNA
Luminal A tumors show great heterogeneity in terms of
somatic mutations and CNA [10], indicating that additional
substructure may be present within this large group. Dis-
secting the genetics of this tumor could be fundamental to
inform therapeutics and predict clinical outcome.
We first explored the spectrum of copy number changes
across Luminal A tumors, to identify novel and subset-
specific alterations. We performed hierarchical clustering
of Affymetrix 6.0 SNP copy number data from 209
Luminal A tumors from the TCGA dataset. Segments of
uniform copy number value for each patient were com-
pared to compute the set of unified breakpoints across the
whole dataset, and the so determined set of minimal seg-
ments of change were used as features for the clustering
procedure. Hierarchical clustering of copy number changes
across the whole genome on the TCGA dataset revealed a
complex structure of recurrent patterns of alterations.
Based on clustering results and recurrent CNA, we were
able to identify four major characteristic patterns and a
mixed group (Fig. 2a; Table S1).
The first major pattern is characterized by 1q gain and
16q loss (1q/16q pattern, clusters a, b, and c). This pattern
has been frequently observed in breast tumors and has been
associated with the translocation der(1;16) [32, 33]. The
1q/16q pattern is dominant in cluster a, which features
otherwise mostly diploid genomes. By contrast, cluster b is
characterized by a broad deletion occurring on 6q, and
cluster c has concurrent 11q13–14 focal amplification and
11q loss. High level amplification of the 11q13 and 11q14
loci is frequently observed in breast tumors and minimal
regions of overlap target CCND1 and PAK1, respectively.
Notably, these amplicons significantly co-occur with loss
of the remaining part of the 11q arm across all tumors in
the TCGA dataset (p = 6E-8, by one-tail-Fisher’s exact
test).
Another group of Luminal A patients is characterized by
a surprisingly quiet copy number spectrum (Copy Number
Quiet pattern). These tumors (cluster d) have almost
completely diploid genomes, with only few cases showing
whole arm loss of 16q.
The third group includes clusters e, f, and g, and is
strongly characterized by CNA of chromosome 8, with loss
of 8p and gain of 8q (Chr8-associated pattern). Within this
group, cluster f shows an interesting pattern of CNA, where
8p loss and 8q gain co-occur with 16p gain and 16q loss.
These gains and losses affect the whole arms of the chro-
mosomes, and in this group they do not co-occur with other
CNAs. Cluster g, on the other hand, displays more copy
number changes and is enriched for focal amplifications of
8p11.23–22 (FGFR1, ZNF703, and WSHC1L1), 8p11.21
(IKBKB), and 11q13–14 (Table S2).
The fourth group is characterized by the highest level of
genomic instability among Luminal A tumors, including
multiple focal CNAs (CNH pattern, cluster h). This group
shows recurrent 20q gain, 5q loss, 8p loss, 8q gain, and is
enriched for focal amplifications of the MYC oncogene on
8q24.21 (Table S2). Finally, the Mixed group is charac-
terized by frequent whole-arm and whole-chromosome
gains and losses, lacking the recognizable patterns seen in
the other four groups (cluster i).
We validated our clusters using the 721 Luminal A sam-
ples from the METABRIC dataset [12]. We classified these
tumors using centroids derived from the TCGA Luminal A
dataset to identify clusters with the same alteration patterns
(Fig. S2; Table S3). The clusters obtained from the META-
BRIC dataset occurred in similar proportions as the TCGA
clusters and their quality was confirmed by the IGP [27]
measure (Fig. 2b). Interestingly, the CN-Quiet and Chr.8-
associated clusters show strong correspondences with two of
the Luminal-enriched clusters from METABRIC and col-
leagues (IC4 and IC7, respectively), whereas components of
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the Mixed and CN-High groups are spread across multiple
clusters (Fig. 2c).
The landscape of Luminal A somatic mutations
Distinct copy number patterns frequently come in tandem
with equally variable landscapes of somatic mutations.
Indeed, despite the lowest mutation rate among breast
cancer subtypes, the Luminal A subtype shows the largest
number of genes mutated with statistically significant
recurrence (Fig. 3a; Table 2).
The most frequently mutated genes ([10 %) are
PIK3CA, GATA3, MAP3K1, and TP53. Interestingly, all
show significant associations with recurrent copy number
patterns. PIK3CA and GATA3 mutations are mostly found
in tumors with low CNA (CN-Quiet and 1q/16q), and in
particular GATA3 mutations are enriched for the 1q/16q
subgroup (pGATA3 = 0.009). Notably, 9 out of 15 hotspot
mutations for GATA3 are in this subgroup. MAP3K1
mutations are enriched in the Chr.8-associated subgroup
(pMAP3K1 = 4.22E-04). MAP3K1 mutations strongly co-
occur with the 8p-/8q?/16p?/16q- pattern observed in
cluster f (pMAP3K1(f) = 1.9E-5), and thus, are largely
mutually exclusive with focal amplification of 8p11.23–21
(Fig. 3b). All MAP3K1-mutated cases harbor at least one
inactivating mutation, indicating loss of function, and most
of them have at least two mutations, suggesting bi-allelic
inactivation (Fig. 3c). Finally, the CNH subgroup shows an
overall depletion for all recurrent Luminal A mutations,
except for a strong presence of TP53 mutations
(pTP53 = 9.35E-6).
Luminal A tumors show also an interesting presence of
hotspot mutations beyond PIK3CA and GATA3. AKT1
E17K activating mutations were observed in 3 out of 4
datasets and predominantly in Luminal A tumors (14 out of
20). Interestingly these mutations are perfectly mutually
exclusive with those targeting PIK3CA. Additional hotspot
mutations include those targeting KRAS (G12V/D),
Chromosomes
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Fig. 2 Copy number clustering of Luminal A breast tumors.
a Hierarchical clustering of copy number data from 209 Luminal A
tumors from the TCGA dataset reveals four distinct patterns of
alterations, plus a mixed subgroup. Chromosomes are arranged from
left to right, and tumors are arranged vertically and grouped according
to cluster membership. Red indicates copy number gain, blue copy
number losses, with color intensity proportional to absolute copy
number values. b Cluster centroids were used to classify the
METABRIC dataset (721 samples). Clusters in the METABRIC
dataset show similar proportions to the TCGA counterparts, and the
quality of the clusters is confirmed by statistically significant IGP.
c Clusters determined from the METABRIC dataset are compared
with the breast cancer subtypes proposed in [12]. Lines connect
clusters with non-empty overlap with a thickness proportional to the
extent of overlap
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Significant Enrichment (p < 0.01)
(A)
(B) (C)
Fig. 3 Landscape of Luminal A somatic mutations. a An unbiased
enrichment analysis shows that PIK3CA mutations are significantly
enriched in the 1q/16q subgroup, MAP3K1 mutations in the Chr8-
associated, and TP53 mutations in the CNH subtgroup. All recurrent
Luminal A mutations are displayed (one mutated gene per row).
Mutations are color coded based on type (dark blue frame-shift,
splice-site, and nonsense/light blue missense) and recurrent hotspots
(red). All TCGA tumors, grouped by copy-number subtype, are
shown in columns, together with mutated cases from the Sanger [13],
WashU [11], and Broad [16] datasets. b MAP3K1 mutations are
strongly associated with a subset of the Chr8-associated cluster
characterized by 8p-/8q?/16p?/16q-. The heatmap shows copy
number profiles for all the Chr.8-associated samples (arranged
vertically). The panel on the right shows that high level amplification
in 8p11 and mutations at MAP3K1 are largely mutually exclusive and
characterize distinct subgroups of tumors in this Luminal A subtype.
c Most patients affected by MAP3K1 mutations have more than one
mutation, suggesting bi-allelic inactivation. The plot shows all
samples with at least one MAP3K1 mutation (X axis), and the actual
number of MAP3K1 mutations for each sample (Y axis)
Table 2 Recurrent somatic mutations of breast cancer subtypes [10, 11, 16]
Subtype No. of non-silent
mutations per sample (avg)
No. of recurrently
mutated (RM) genes
RM genes: FDR \ 0.05
Luminal A 27 28 PIK3CA, MAP3K1, GATA3, TP53, CDH1, MLL3,
MAP2K4, NCOR1, AKT1, PTEN, RUNX1, CTCF,
CBFB, SF3B1, MED23, WNT7A, TBL1XR1,
TBX3, GPS2, FOXA1, DGKG, SMCHD1, KRAS,
CCND3, NKAIN4, HIST2H2BE, HIST1H3B, SHD,
GPR32
Luminal B 38 15 PIK3CA, TP53, GATA3, CDH1, MAP3K1, RUNX1,
PTEN
OR2L2, TBX3, MAP2K4, AKT1, KCNB2, RB1,
PRRX1, HIST1H3B
Basal-like 55 5 TP53, PIK3CA, PNPLA3, C11orf85, HLF
Her2-enriched 61 4 TP53, PIK3CA, SRPR, PIK3R1
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splicing factor SF3B1 (K666E, K700E), and c-Myc tran-
scriptional repressor CTCF (R283C, H284P/Y/N).
Associations with clinical outcome reveal high-risk
Luminal A subtype
The characterization of Luminal A tumors provided so far
clearly identifies distinct subgroups within this tumor
subtype, whose clinical relevance needs to be addressed
now. The large dataset analyzed by Curtis et al. [12] has
extensive clinical follow-up, enabling a reliable survival
analysis. Kaplan–Meier analysis showed significantly dif-
ferent disease survival within the Luminal A subgroups
(log-rank p = 0.015, Fig. S4). In particular, the CNH
subgroup had significantly worse outcome (log-rank
p = 4.6E-5, Fig. 4a) despite receiving similar treatments
(Table S3). We validated the poor prognosis for the CNH
tumors in an independent dataset consisting of 77 Luminal
A tumors from three different cohorts [19] (log-rank
p = 0.003, Fig. 4b; Table S4).
To assess dependencies between the CNH classification
and other clinical covariates, we used Cox multivariate
regression. We tested for dependencies for tumor grade,
stage, size, and age at diagnosis. We found independent
statistically significant association with outcome for tumor
size (p = 6E-05), age at diagnosis (p = 0.004), and CNH
classification (p = 0.01); no association was found
between these covariates. The overall log-rank p-value for
the combined covariates is p = 2E-08. The CNH classi-
fication showed, therefore, independent prognostic value
(Table S5).
Finally, we compared scores derived from research-
based versions of Oncotype DX [1], Mammaprint [34], and
PAM50 Risk of Recurrence (ROR-S) [8] across Luminal A
subgroups. We found that the CNH subgroup is consis-
tently associated with a higher risk than the other Luminal
A subgroups (Fig. S5), confirming the prediction of a worse
prognosis.
As shown above, the CNH tumors are (1) characterized
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Fig. 4 CNH tumors. a Survival analysis across two independent
datasets shows significantly worse outcome for the CNH Luminal A
tumors. b Unbiased enrichment analysis of genomic alterations found
CNH tumors to be enriched for TP53 mutations, focal amplification of
MYC, 5q loss, 20q gain, and depleted for PIK3CA mutations.
c Differential expression analysis shows that significantly up-
regulated genes in CNH tumors are enriched for regulators of mitosis
and Aurora kinase pathway components. The heatmap shows all
genes that are differentially expressed in CNH tumors when compared
to other Luminal A samples (red indicates high expression, green low
expression). Aurora kinase is a mitotic serine/threonine kinase that
phosphorylates multiple proteins including PLK1 and Cdc25; it is
required for CDK1 activation and regulates mitotic events
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Luminal A mutations (e.g., PIK3CA, 29 vs. 51 %,
pPIK3CA = 0.04), (3) highly enriched for TP53 mutations
(48 vs. 7 % on average in the other Luminal A samples),
and (4) tend to have MYC focal amplification, 20q gain
and 5q loss (Fig. 4c). Interestingly, genes that are signifi-
cantly over-expressed in CNH tumors compared to the rest
of Luminal A cases are enriched for regulators of mitosis
including Aurora kinases A and B, PLK1, Cyclin-A,
Cyclin-E, CDK1, and Cdc25 (Fig. 4d; Table S6). A similar
set of genes was previously found to be associated with 5q
loss in Basal-like breast cancers [12]. Most of these genes
have also been identified as ‘‘proliferation marker’’ genes
[35]. The observed clinical outcome for CNH tumors,
confirmed in two independent datasets, is therefore
strongly associated to high genomic instability and prolif-
eration as revealed by their molecular features.
Integrated pathway analysis reveals mechanisms
of resistance to endocrine therapy
The great diversity of genomic lesions observed in Luminal
A tumors maps to different cellular processes. To explore
the role of these alterations in a pathway context, we used
the MEMo algorithm [31], which identifies micro-path-
ways or modules whose components are frequently altered
in a mutually exclusive manner. Statistically significant
mutual exclusivity between recurrent alterations strength-
ens the hypothesis of functional relatedness and, more
importantly, may reflect either functional redundancy,
highlighting multiple ways to de-regulate the same path-
way, or synthetic lethal interactions [31].
Modules extracted by MEMo in a Luminal A-only
analysis highlight frequent alteration to the PI(3)K/Akt,
MAP-kinase, and Ras/ERK signaling cascades (Figs. 5a,
S3; Table S7). Alterations include PTEN inactivation,
mutations of PIK3CA and AKT1, inactivation of MAP3K1
and MAP2K4, amplification of receptor tyrosine kinases
(ERBB2 and IGF1R), and RAS activation either through
activating mutations of KRAS or NF1 depletion by either
DNA homozygous deletion or mRNA down-regulation
(Fig. S6). Mutually exclusive inactivation of MAP3K1 and
MAP2K4 was confirmed in the Ellis et al. [11] dataset,
corroborating the hypothesis of reduced JNK signaling in
Luminal A tumors and providing further insights into
MAP3K1 mutations.
MEMo also identified a set of less frequent alterations
targeting the N-Cor and SMRT complexes (Fig. 5b). While
not statistically significant due to the small number of
altered samples (28 out of 209 in total), alterations in these
modules are almost completely mutually exclusive. Alter-
ations include recurrent mutations targeting core compo-
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Fig. 5 Pathway analysis. Altered pathways across Luminal A tumors
identified by the MEMo algorithm. a MEMo identified multiple
modules recapitulating Akt, MAPK, and Ras signaling. Gene
activation is shown in shades of red, inactivation in shades of blue.
b MEMo found network modules highlighting multiple alterations of
nuclear co-repressors. Genes are arranged vertically, and altered
tumors from left to right. c Nuclear co-repressors and co-activators
regulate ER transcription and Tamoxifen anti-proliferative effects.
d Alterations identified by MEMo compromise co-repressor activities
and may predict response to therapy
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TBL1XR1, and GPS2) and the nuclear co-repressor 2
(NCOR2) or SMRT. Most of these mutations are either
frame-shift or nonsense and thereby likely inactivating,
they correlate with low mRNA expression, and frequently
co-occur with hemizygous loss of the target gene. The
modules also include homozygous deletions of ANKRD11,
consistent with its ability to inhibit p160 steroid receptor
co-activator recruitment [36, 37].
Co-repressor and co-activator complexes play a major
role in regulating ER-a transcription and the inhibitory
activity of Tamoxifen. Tamoxifen-bound ER has an
increased affinity to co-repressors and specifically to
N-Cor/SMRT. These co-repressors are required for the
anti-proliferative effects of Tamoxifen (Fig. 4c). Repress-
ing the NCor and SMRT complexes in human breast cancer
cell lines turns Tamoxifen into an agonist of cell prolifer-
ation [38, 39], and lower or absent mRNA expression of
NCor in patients correlates with shorter relapse [40, 41].
Here, for the first time, we identify distinct molecular
mechanisms of inactivation of these complexes in patients.
We directly link multiple genomic alterations, occurring in
13 % of the patients, to loss of co-repressors activity
(Fig. 4d). These alterations may predict resistance to
endocrine therapy.
Discussion
Recently, multiple studies of human breast cancer provided
novel insights into the biology of this cancer and its
intrinsic subtypes [7], as well as an unprecedented amount
of genomic information still not completely explored and
understood. This information is fundamental to inform
patient treatments with targeted agents [42, 43]. Our work
aimed at complementing recent breast cancer genomic
studies, with an in-depth analysis of the most diverse breast
cancer subtype: Luminal A. We dissected the genomics of
Luminal A tumors in multiple datasets and have explained
more of its molecular and clinical heterogeneity.
We identified four major subgroups of Luminal A
tumors that are characterized by distinct patterns of CNA,
somatic mutations, and clinical outcomes (Table 3). These
include a subgroup (i.e., CNH) presenting molecular fea-
tures atypical of Luminal tumors and associated with
worse prognosis. Poor clinical outcome was confirmed in
multiple datasets and is independent of other markers, such
as tumor size, grade, stage, and age of diagnosis. Inter-
estingly, the CNH distinction was also associated with
higher scores coming from current clinical assays for
breast cancer prognosis/prediction (Oncotype DX, Mam-
maprint, PAM50 ROR-S), thus providing a molecular
explanation for these gene expression risk assays. This
subtype shows a high level of CNA, recurrent TP53
mutations, and over-expression of mitotic regulators
including Aurora kinases A and B (Table 3). Over-
expression of these genes has been associated with high
genomic instability and tumorigenesis [44, 45] and, more
importantly, Aurora kinases are targets of specific inhibi-
tors currently in clinical trials [46].
Integrated analysis of CNA and mutations showed a sig-
nificant prevalence of GATA3 and PIK3CA hotspot muta-
tions in tumors characterized by 1q gain and 16q loss; thus,
the tumors with the fewest copy number changes showed not
only associations with mutations within specific genes, but
associations with distinct types of mutations within these
genes. These results suggest that one type of mutation within
GATA3 (i.e., intron 4 CA deletion) is strongly associated
Luminal A 1q/16q cancers, while other mutations (exon 5
frameshifts) cause Luminal B cancers; thus, these mutations
are likely to be cancer driving events, and early events within
the evolution of these tumors.
Mutations within the PI3K pathway became of partic-
ular clinical interest with the advent of many specific
PIK3CA inhibitors now in clinical trials [42, 47]. Of
particular interest will be if the different pathway muta-
tion types (PIK3CA mutation vs. PTEN mutation vs.
AKT1 mutation) are all biomarkers of PIK3CA inhibitor
sensitivity, and how these might interact with the different
Table 3 Genomic features of Luminal A Copy Number Subtypes
Focal CNA Whole-arm events Somatic mutations
1q/16q 16q23-24 HomDel (ANKRD11) 1q gain, 16q loss PIK3CA, PIK3R1, GATA3,
AKT1, KRAS
Copy Number Quiet None None PIK3CA, AKT1
Chr8-associated 8p11.23-22 Amp (ZNF703,
WHSC1L1, FGFR1)




Copy Number High 8p24.21 Amp (MYC) 8q gain, 5q loss, 20q gain TP53
20q13.2 Amp (AURKA, ZNF217)
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inhibitors, many of which have differing affinities for the
PI(K) family of kinases. Lastly, multiple inactivating
mutations in MAP3K1 were found in tumors with whole-
arm events on chromosome 8 and 16. Alterations of these
genes point to deregulated AKT and MAPK signaling,
and this was confirmed by an unbiased pathways analysis.
In particular, MAP3K1 and its direct target MAP2K4
negatively regulate JNK-mediated cell death, possibly
compromising response to chemotherapeutic agents [48];
thus, a pressing clinical question is do mutations in
MAP3K1 and/or MAP2K4 predict for lower response
rates to chemotherapy and endocrine therapy, which can
be addressed retrospectively if mutation detection can be
performed using FFPE materials from existing clinical
trial archives.
Our analysis of deregulation of cellular pathways in
Luminal A tumors also revealed inactivation of the ER co-
repressors N-Cor/SMRT. We identified multiple rare, but
mutually exclusive, alterations targeting components of
these complexes, as well as ANKRD11, an inhibitor of
p160 co-activator complexes. Nuclear co-repressors regu-
late ER transcriptional activity and are required for the
anti-proliferative effects of Tamoxifen [40, 41]. Alterations
of these complexes may, therefore, promote ER-driven
proliferation in the presence of Tamoxifen, and predict a
lack of response to endocrine therapy. These alterations
were observed almost exclusively in Luminal A tumors.
Indeed, the same unbiased pathway analysis performed on
the whole TCGA breast cancer dataset was unable to
highlight them [10].
Our work integrated multiple genomic and genetic data
types within the Luminal A breast cancer subtype and
spanned multiple data sets. Our results have shed new light
on the intrinsic heterogeneity within this subtype and
strengthen the importance of genomic studies within tumor
subpopulations. These in-depth analyses already show
intrinsic heterogeneity in other breast cancer subtypes. Her-
2 positive tumors have been shown to be composed of two
main groups defined by different ER and EGFR status [10],
and recently Her-2 mutations have been shown to be
activating and tumorigenic [49] in tumors without DNA
amplification of the Her-2 locus. Moreover, these muta-
tions are prominent in relapsed invasive lobular breast
cancer [50]. Similarly, basal-like and triple negative breast
cancers have been object of extensive investigations due
their aggressive nature [51–53]. We can now add Luminal
A disease to the list of heterogeneous diseases with distinct
subtypes within this previously defined single subtype. The
wealth of genomic data available today enables these in-
depth analyses of selected tumor subgroups and highlights
the need for comprehensive genomic characterization of
tumor samples to inform clinical trials and therapeutic
choices.
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